Azur Pharma plc

Merger & acquisition (M&A) activity among pharmaceutical and bioscience companies has shown no signs of slowing down. More importantly, even though AstraZeneca's rejection of Pfizer's $120bn plus take

Jazz Pharmaceuticals Inc. is poised to undertake “good transactions,” with a priority set on products that are currently on or close to the market, CFO Kathryn Falberg told analysts on a second-quart

Through a series of acquisitions Jazz Pharmaceuticals PLC has managed to double both its top-and bottom-line growth over the last year, but its narcolepsy drug Xyrem (sodium oxybate) is still th

Jazz Pharmaceuticals has completed the sales of its women's health business to Meda of Sweden for $95 million in cash. The six products being transferred generated sales of $30.4 million in 2011, and